Costs, Quality of Life and Disease Severity in Multiple Sclerosis - A Population-Based Cross-Sectional Study in Sweden
This study has used a cross-sectional, 'bottom-up' design to determine the cost to society of multiple sclerosis (MS) in Sweden in 1998. The total cost of MS was estimated at 4 868 MSEK, meaning an annual cost of 442 500 SEK per patient. Direct costs accounted for about 67% of total cost, and direct costs were dominated by the cost of personal assistants and drugs. Indirect costs accounted for about 33% of total costs and were totally dominated by the cost of long-term sickness absence from work and early retirement. Intangible costs were estimated at 2 700 MSEK. A former Swedish study on MS for 1994, using main diagnosis to calculate costs, showed the total cost to be 1 736 MSEK. Increased disability as measured by EDSS was found to have a major impact on the cost of the disease and on quality of life. Both direct, indirect and informal care costs rose significantly with increased EDSS and were higher during a relapse. Quality of life declined substantially with increased EDSS and was lower during a relapse. In summary, this study showed that a severe, chronic, disabling disease like MS that strikes early in life has major implications for both the society as a whole and for the affected patients.
|Date of creation:||06 Mar 2000|
|Date of revision:|
|Contact details of provider:|| Postal: The Economic Research Institute, Stockholm School of Economics, P.O. Box 6501, 113 83 Stockholm, Sweden|
Phone: +46-(0)8-736 90 00
Fax: +46-(0)8-31 01 57
Web page: http://www.hhs.se/
More information through EDIRC
References listed on IDEAS
Please report citation or reference errors to , or , if you are the registered author of the cited work, log in to your RePEc Author Service profile, click on "citations" and make appropriate adjustments.:
- Niklas Zethraeus & Magnus Johannesson, 1999. "A comparison of patient and social tariff values derived from the time trade-off method," Health Economics, John Wiley & Sons, Ltd., vol. 8(6), pages 541-545.
When requesting a correction, please mention this item's handle: RePEc:hhs:hastef:0361. See general information about how to correct material in RePEc.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: (Helena Lundin)
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
If references are entirely missing, you can add them using this form.
If the full references list an item that is present in RePEc, but the system did not link to it, you can help with this form.
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your profile, as there may be some citations waiting for confirmation.
Please note that corrections may take a couple of weeks to filter through the various RePEc services.